Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

BACKGROUND: Patients with inflammatory bowel disease who achieve remission with anti-tumour necrosis factor (anti-TNF) drugs may have treatment withdrawn due to safety concerns and cost considerations, but there is a lack of prospective, controlled data investigating this strategy. The primary study...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaparro, María, Donday, María G., Barreiro-de Acosta, Manuel, Domènech, Eugeni, Esteve, María, García-Sánchez, Valle, Nos, Pilar, Panés, Julián, Martínez, Concepción, Gisbert, Javier P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832302/
https://www.ncbi.nlm.nih.gov/pubmed/35154384
http://dx.doi.org/10.1177/1756284819874202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832302/
https://www.ncbi.nlm.nih.gov/pubmed/35154384
http://dx.doi.org/10.1177/1756284819874202

Ejemplares similares